CTDNA

This study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 adults with stable disease will r…

This study is for people with high-risk stage III colorectal cancer. It tests whether using a blood test (ctDNA) to guide treatment decisions can improve outcomes. Participants will receive either standard chemotherapy or chemotherapy plus bevacizumab, with regular blood monitori…

This study is for people with stage I or low-risk stage II colorectal cancer who have a positive ctDNA blood test one month after surgery, indicating a higher risk of recurrence. Researchers will assign different chemotherapy regimens based on ctDNA results to see if this persona…

This study is for people with high-risk stage II colorectal cancer who have a positive blood test for tumor DNA one month after surgery. It tests whether using that blood test to choose stronger or different chemotherapy can help clear the tumor DNA and prevent the cancer from co…

This study tests whether using a blood test that detects tumor DNA can help doctors decide how long chemotherapy should last for people with certain types of colorectal cancer. About 340 adults with stage II or low-risk stage III colorectal cancer will be randomly assigned to sta…

This study explores whether monitoring tumor DNA in the blood (ctDNA) can help guide treatment for esophageal cancer. Researchers will give patients immunotherapy and chemotherapy, followed by chemoradiotherapy, and track ctDNA levels to see if they predict outcomes. The goal is …

This study tests whether a blood test that tracks tumor DNA (ctDNA) can help doctors decide when to intensify treatment for HER2-negative metastatic breast cancer. All 122 participants start with antibody-drug conjugate (ADC) therapy. After two cycles, those whose disease hasn't …

This study is testing a blood test that looks for DNA changes from tumors to help diagnose and manage biliary tract cancers, which are often found late and have a low survival rate. Researchers will enroll 1,800 participants with confirmed cancers to see how accurate the test is.…

This study is testing whether a blood test that looks for cancer DNA (called ctDNA) can find leftover cancer cells after surgery in people with colorectal cancer that has spread to the liver. The goal is to see which test works best at predicting if the cancer will come back. Thi…